A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study
American Journal of Hematology · 2025
DOI: 10.1002/ajh.27516 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Hui Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit nennt 6 Literaturangaben. Gefördert von: Clinical Research Program of Nanfang Hospital, Southern Medical University, National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Relapse is the major cause of treatment failure in Philadelphia chromosome‐positive (Ph + ) acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT). This study aimed to evaluate the effect of a prophylactic tyrosine kinase inhibitor (TKI) strategy on relapse in this population. Patients were assigned to prophylactic or control groups based on measurable residual disease (MRD) pre‐transplantation. The primary endpoint was the cumulative incidence of relapse. A total of 110 patients with Ph + ALL undergoing allo‐HSCT were enrolled in this prospective study. Thirty‐eight patients with positive MRD pre‐transplantation were included in the prophylactic group, and 72 with negative MRD pre‐transplantation were included in the control group. The 4‐year cumulative incidence of relapse was 25.3% (95% CI: 12.1%–41.0%) and 20.3% (11.6%–30.7%; HR = 1.272, 95% CI: 0.551–2.940, p = .549), and non‐relapse mortality was 10.5% (3.3%–22.7%) and 9.7% (4.2%–17.9%; HR = 1.094, 95% CI: 0.320–3.738, p = .928) in the prophylactic and control groups. The 4‐year overall survival was 71.8% (53.2%–84.1%) and 84.1% (72.9%–90.9%; HR = 1.746, 95% CI: 0.741–4.112, p = .196), and leukemia‐free survival was 64.1% (45.8%–77.7%) and 70.0% (57.6%–79.4%; HR = 1.212, 95% CI: 0.607–2.421, p = .585) in the prophylactic and control groups. Our results suggest that prophylactic TKI post‐HSCT in patients with positive MRD pre‐transplantation can produce outcomes comparable to negative MRD pre‐transplantation without TKI post‐HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Hematology, Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
- Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Hematology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Hematology, First People's Hospital of Chenzhou, Chenzhou, China.
ORCID-Profile: Hua Jin, Hongsheng Zhou, Qifa Liu, Li Xuan
Förderung
- Clinical Research Program of Nanfang Hospital, Southern Medical University
- National Key Research and Development Program of China
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Liu, H., Xu, H., Chi, P., Feng, Z., Xu, X., Nie, D., Li, X., Liang, X., Fan, Z., Xu, N., Huang, F., Lin, R., Wang, Z., Jin, H., Zhou, H., Guo, X., Lin, D., Sun, J., Liu, Q., & Xuan, L. (2025). A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study. American Journal of Hematology. https://doi.org/10.1002/ajh.27516
Vancouver
Liu H, Xu H, Chi P, Feng Z, Xu X, Nie D, et al. A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study. American Journal of Hematology. 2025. doi:10.1002/ajh.27516
BibTeX
@article{Liu2025,
author = {Liu, Hui and Xu, Hui and Chi, Peiru and Feng, Zinan and Xu, Xiaojun and Nie, Danian and Li, Xudong and Liang, Xinquan and Fan, Zhiping and Xu, Na and Huang, Fen and Lin, Ren and Wang, Zhixiang and Jin, Hua and Zhou, Hongsheng and Guo, Xutao and Lin, Dongjun and Sun, Jing and Liu, Qifa and Xuan, Li},
title = {A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.27516}
}
EUVIMED